Payment overview · 2025
General Payments
$1,384.16
62 reported records · 18 companies
Healthcare provider profile · identity verified
Michael C Adams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GRANITE CITY, IL · NPI 1851383301
Verified facts
What the public records show
CMS Open Payments records show Michael C Adams, MD received $1,384.16 in general payments during 2025 across 62 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $405.36 | 29.3% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.02 | 15.0% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.01 | 12.9% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $143.58 | 10.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.30 | 5.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.14 | 3.8% | 3 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.82 | 3.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.54 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.70 | 2.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.23 | 2.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.42 | 2.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.01 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.39 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.83 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.96 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.34 | 1.3% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $16.65 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.86 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,384.16 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $332.30 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $271.53 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $228.21 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $143.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.96 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $97.82 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $94.06 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.19 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.19 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.73 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.14 | 4 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.55 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 169 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
169 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
191 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1209 | 373 |
| Amlodipine Besylate | Amlodipine Besylate | 592 | 170 |
| Lisinopril | Lisinopril | 538 | 149 |
| Metformin Hcl | Metformin Hcl | 443 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 99 |
| Losartan Potassium | Losartan Potassium | 298 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 100 |
| Montelukast Sodium | Montelukast Sodium | 295 | 85 |
| Furosemide | Furosemide | 292 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 87 |
| Carvedilol | Carvedilol | 230 | 64 |
| Omeprazole | Omeprazole | 225 | 69 |
| Gabapentin | Gabapentin | 222 | 59 |
| Alprazolam | Alprazolam | 213 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 62 |
| Ezetimibe | Ezetimibe | 201 | 60 |
| Sertraline Hcl | Sertraline Hcl | 199 | 59 |
| Simvastatin | Simvastatin | 194 | 63 |
| Ozempic | Semaglutide | 191 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 54 |
| Farxiga | Dapagliflozin Propanediol | 169 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 42 |
| Glimepiride | Glimepiride | 140 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 35 |
| Azithromycin | Azithromycin | 132 | 102 |
| Nifedipine Er | Nifedipine | 132 | 41 |
| Lorazepam | Lorazepam | 126 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 35 |
| Allopurinol | Allopurinol | 117 | 33 |
| Potassium Chloride | Potassium Chloride | 117 | 36 |
| Famotidine | Famotidine | 113 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 21 |
| Eliquis | Apixaban | 108 | 35 |
| Meloxicam | Meloxicam | 107 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 29 |
| Metformin Hcl Er | Metformin Hcl | 96 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 81 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 77 | 14 |
| Trazodone Hcl | Trazodone Hcl | 77 | 22 |
| Buspirone Hcl | Buspirone Hcl | 71 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 26 |
| Finasteride | Finasteride | 70 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 67 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Prednisone | Prednisone | 63 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 20 |
| Methylprednisolone | Methylprednisolone | 60 | 52 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 59 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 44 |
| Atenolol | Atenolol | 53 | 15 |
| Spironolactone | Spironolactone | 53 | 15 |
| Warfarin Sodium | Warfarin Sodium | 52 | 11 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Clonidine Hcl | Clonidine Hcl | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 46 | 13 |
| Mirtazapine | Mirtazapine | 44 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Jardiance | Empagliflozin | 42 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 25 |
| Diazepam | Diazepam | 37 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 12 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | 11 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Primidone | Primidone | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 23 |
| Valsartan | Valsartan | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 14 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,384.16 · 62 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APLENZIN, APRETUDE, AREXVY, BEXSERO, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, ETERNA, EVENITY, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRUMENBA, UBRELVY, VAXNEUVANCE, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error